Connect with us

Industry News

Medical Marijuana, Inc. Announces Second Quarter Filing Date and Schedules Investor Conference Call for August 15, 2019

Avatar

Published

on

default_cannabis_industry_cannamaps

SAN DIEGO, Aug. 12, 2019 (GLOBE NEWSWIRE) — Medical Marijuana, Inc. (OTC: MJNA), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands and supply chain, today announced that the Company will file its second quarter financial and operational results on August 14 and will host an investor conference call at 4:30 PM ET on Thursday, Aug. 15, to discuss earnings for the quarter ending June 30, 2019.
Medical Marijuana, Inc. CEO Dr. Stuart Titus and COO Blake Schroeder will provide updates on the financial and operational performance of the Company in the second quarter of 2019, share recent research and development progress, and discuss where the company is headed for the remainder of the year and in the future.“We are excited to share our second quarter success and help shareholders understand the initiatives the Company is currently pursuing,” said Medical Marijuana, Inc. CEO Dr. Stuart Titus. “We are optimistic that our transparency will provide confidence and clarity on where the future of Medical Marijuana, Inc. is headed.”Interested parties have the opportunity to submit questions concerning the Company prior to the call to Stuart Smith at SmallCapVoice.com, Inc. via email: ssmith@smallcapvoice.com by 12:00 PM ET on Wednesday, Aug. 14.  Prior to the call, Mr. Smith will provide the Company with a list of submitted questions based on the relevance to the shareholder base and the question’s appropriateness concerning public disclosure rules.To access the call:Dial-In Number: 1-857-232-0157
Access Code: 422095
For those unable to attend the conference call, a replay will be available at https://www.smallcapvoice.com/tag/mjna/ shortly after the call has concluded.About Medical Marijuana, Inc.We are a company of firsts®.  Medical Marijuana, Inc. (MJNA) is a cannabis company with three distinct business units in the non-psychoactive cannabinoid space: a global portfolio of cannabinoid-based nutraceutical brands led by Kannaway® and HempMeds®; a pioneer in sourcing the highest-quality legal non-psychoactive cannabis products derived from industrial hemp; and a cannabinoid-based clinical research and botanical drug development sector led by its internal R&D and scientific team and its pharmaceutical investment companies and partners including AXIM® Biotechnologies, Inc. and Kannalife, Inc. Medical Marijuana, Inc. was named a top CBD producer by CNBC. Medical Marijuana, Inc. was also the first company to receive historic import permits for CBD products from the governments of Brazil, Mexico, Argentina, and Paraguay and is a leader in the development of international markets. Medical Marijuana, Inc.’s headquarters is in San Diego, California, and additional information is available at OTCMarkets.com or by visiting www.medicalmarijuanainc.com.To see Medical Marijuana, Inc.’s corporate video, click here.Shareholders and consumers are also encouraged to buy CBD oil and other products at Medical Marijuana, Inc.’s shop.FORWARD-LOOKING DISCLAIMERThis press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSUREThese statements have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease.LEGAL DISCLOSURE
Medical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). These companies do grow, sell, and distribute hemp-based products and are involved with the federally legal distribution of medical marijuana-based products within certain international markets. Cannabidiol is a natural constituent of hemp oil.
CONTACT:
Public Relations Contact:
Andrew Hard
Chief Executive Officer CMW Media
P. 858-264-6600
andrew.hard@cmwmedia.com
www.cmwmedia.com

Original story can be found at: http://www.globenewswire.com/news-release/2019/08/12/1900513/0/en/Medical-Marijuana-Inc-Announces-Second-Quarter-Filing-Date-and-Schedules-Investor-Conference-Call-for-August-15-2019.html?f=22&fvtc=5&fvtv=41223728

Continue Reading

Industry News

AGCO releases results of the second cannabis lottery: 42 applicants notified to apply for a cannabis Retail Store Authorization in Ontario

Avatar

Published

on

default_cannabis_industry_cannamaps

TORONTO, Aug. 21, 2019 (GLOBE NEWSWIRE) — The Alcohol and Gaming Commission of Ontario (AGCO) has released the results of the cannabis retail store lottery draw it held on August 20, 2019. The lottery provided those who met pre-qualification requirements for one of the 42 new store authorizations announced by the Government of Ontario on July 3, 2019, an opportunity to be selected to apply for one.
4,864 eligible expressions of interest were included in the lottery draw, which was overseen by a third-party fairness monitor. The AGCO has notified the following 42 selected applicants that they may now apply for a cannabis Retail Operator Licence and a Retail Store Authorization. Applicants have until August 28, 2019 to do so, at which point the AGCO will undertake its full eligibility and licensing review. The AGCO will only licence applicants and authorize stores that meet all legal and regulatory requirements.SELECTED APPLICANTS AND THEIR PROPOSED STORE LOCATIONSEast Region:GTA Region:North Region:Toronto Region:West Region:ADDITIONAL INFORMATIONAllocation lottery resultsSummary of lottery entries received by regionCannabis Retail Store Allocation Lottery RulesRegistrar’s Standards for Cannabis Retail StoresAbout the AGCO
The Alcohol and Gaming Commission of Ontario (AGCO) is an Ontario provincial regulatory agency reporting to the Ministry of the Attorney General (MAG). The agency was established on February 23, 1998 under the Alcohol, Cannabis and Gaming Regulation and Public Protection Act, 1996.
The AGCO is responsible for regulating the alcohol, lottery and gaming, horse racing and private cannabis retail sectors in accordance with the principles of honesty and integrity, and in the public interest.Media Contact:
Raymond Kahnert, Senior Advisor, Communications
(416) 326-3202, media@agco.ca 
FACT SHEETOn July 3, 2019, the Government of Ontario announced 50 new cannabis retail store authorizations would be made available. Of these 50 new stores, the AGCO will allocate up to 42 authorizations to applicants selected by lottery and eight to stores on First Nations reserves.Applicants who wished to participate in this lottery had to meet pre-qualification requirements, including confirmation from a bank, credit union, or caisse populaire that the applicant has the financial capacity to obtain $250,000 in cash or cash equivalents; confirmation from a bank, credit union, or caisse populaire that the applicant can obtain a Standby Letter of Credit in the amount of $50,000 within five business days of being notified of their selection; confirmation that the applicant has secured a suitable retail space, which will be available to them for operating a cannabis retail store no later than October 2019The required bank letters were provided to the lottery applicants by over 25 banking institutionsOnce the AGCO receives Retail Store Authorization applications from those selected in the lottery, residents of the community in which a store is proposed to be located will have an opportunity to provide written submissions if they believe the location of the store is not in the public interest, as defined by Ontario Regulation 468/18 made under the Cannabis Licence Act, 2018It is anticipated that stores will begin to open starting in October 2019, as they are readyThe AGCO has placed the applicants not selected in the lottery on Wait Lists for each Region, based on the order in which they were drawn. Applicants on the Wait List will be moved to the selected list if those ahead of them are found to be ineligible for a licence/authorization or are otherwise disqualifiedIn the future, if the Government proceeds with additional retail store allocations before moving to an open marketplace, any such allocations may be based on the results from this lottery

Original story can be found at: http://www.globenewswire.com/news-release/2019/08/21/1904954/0/en/AGCO-releases-results-of-the-second-cannabis-lottery-42-applicants-notified-to-apply-for-a-cannabis-Retail-Store-Authorization-in-Ontario.html?f=22&fvtc=5&fvtv=41223728

Continue Reading

Industry News

Infinity Supercritical Announces SDR Model X For Continuous Feed Hemp Oil Processing

Avatar

Published

on

default_cannabis_industry_cannamaps

MADISON, Wis., Aug. 21, 2019 (GLOBE NEWSWIRE) — Infinity Supercritical LLC is introducing its industrial scale hemp oil processors that use water to extract full spectrum oil in under a second. Our modular botanical oil processors can extract oil from your organic hemp, with a capacity of 10,000 lbs to 100,000 lbs per day. The continuous feed process is the only in the industry that uses water as the solvent, to produce a eco-extracted oil, that can be labeled with organic and green branding.
Less than 10 percent of the 2019 hemp crop will be processed at fall harvest from the lack of botanical extractors. Based on the deluge of calls we get from farmers, wanna-be processors, and equity groups, there will be a huge bottleneck at this years fall hemp harvest.Hemp became Federally legal in 2019, which had farmers scrambling to get crops in the ground, many at the last minute in late spring. The lack of coordinated state regulation nationwide has resulted in a patch-work of states under cultivation, some more than ten-fold increase in acreage planted from last year.While many smaller fly-by-night processors turn to ethanol extraction. If not done properly, it produces a poor quality full spectrum hemp CBD oil. A full spectrum oil provides the most benefits to the body. Many operators choose to use activated carbon to filter out the green bitter tasting chlorophyll, which unfortunately also filters out the CBDs. The consumer may not know the difference when purchasing full spectrum oil, aside from being turned off from lackluster results.The result? Much of the hemp crop will go unprocessed, and some will go into long term storage and degrade.Infinity Supercritical LLC offers innovative one-touch processing technology using water as the solvent, and a visionary future for clean and quality full spectrum hemp CBD oil extraction.  Please visit https://sonicextractor.com for more information.G. Giese | CEO | Infinity Supercritical LLC | greg@infinitysupercritical.com

Original story can be found at: http://www.globenewswire.com/news-release/2019/08/21/1904928/0/en/Infinity-Supercritical-Announces-SDR-Model-X-For-Continuous-Feed-Hemp-Oil-Processing.html?f=22&fvtc=5&fvtv=41223728

Continue Reading

Industry News

CURE Pharmaceutical [OTCQB: CURR] Takes First Step To Secure Hemp CBD Supply Chain by Partnering with Fytiko Farms 

Avatar

Published

on

default_cannabis_industry_cannamaps

OXNARD, Calif., Aug. 21, 2019 (GLOBE NEWSWIRE) — CURE Pharmaceutical (OTC: CURR), an innovative drug delivery and development company, today announced it has signed a deal with Oklahoma-based hemp grower Fytiko Farms. The deal gives CURE direct, guaranteed access to high-quality plant material for exclusive use in its proprietary oral thin film (OTF) drug delivery system, CUREfilm®.
“The agreement with Fytiko Farms is a crucial step in CURE’s effort to secure our CBD supply chain and also includes preferred pricing for CURE,” said Rob Davidson, CEO of CURE Pharmaceutical. “This puts CURE in a strategic position to further deliver on our mission to bring the best products to our customers and accelerates our product commercialization. Our next step will be securing a relationship with vendors for the extraction process leveraging our extraction patents.”The deal provides access to high-quality organic hemp extracts for use in CURE products through strain improvement, cannabinoid extraction process development, biomarker identification and quality control testing.“Partnering with an industry leader like CURE allows us to expand into more markets and grow our production capabilities,” said Joe Dan Rogers, CEO of Fytiko Farms. “This partnership supports our main business of growing hemp by providing a production hub for local farmers and marketing our high-quality hemp oil and other byproducts for use in CURE’s hemp-based products.”Fytiko Farms is an innovative company focused on industrial hemp production, cultivation, seed and clone production and sale and the processing and sale of the various by-products from the hemp plant. In 2019, Fytiko Farms was licensed to plant in Oklahoma, utilizing select varieties specifically targeted for their genetics.About CURE Pharmaceutical
CURE Pharmaceutical is a vertically integrated drug delivery and development company committed to improving drug efficacy, safety, and the patient experience through its proprietary drug dosage forms and delivery systems. CURE has a full-service cGMP manufacturing facility and is a pioneering developer and manufacturer of a patented and proprietary delivery system (CUREfilm™), one of the most advanced oral thin film on the market today. CURE is developing an array of products in innovative delivery platforms and partners with biotech and pharmaceutical companies. CURE has positioned itself to advance numerous therapeutic categories, including the pharmaceutical cannabis sector with partnerships in the U.S., Canada, and Israel. The company’s mission is to improve people’s lives by redefining how medicines are delivered and experienced.
For more information about CURE Pharmaceutical, please visit its website at www.curepharma.com.About Fytiko Farms
Fytiko Farms is an innovative company focused on industrial Hemp cultivation, seed and clone production and sale and processing of the various byproducts from the Hemp plant. Fytiko Farms collaborates Murray State College to develop and promote new technologies through research, education, and collaboration in the creation of stable, reliable seed stock for industrial hemp and the cultivation of industrial hemp inside the State of Oklahoma as permitted by the Oklahoma Industrial Hemp Agriculture Pilot Program. Fytiko Farms is licensed to plant and cultivate up to 100 acres for 2019.
For more information about Fytiko Farms, please visit its website at www.fytikofarms.com.This press release contains forward-looking statements that involve risks and uncertainties. There are important factors that could cause actual results to differ materially from those in the forward-looking statements. These factors include, without limitation, the ability to successfully market our products, the difficulty in predicting the timing or outcome of other product research and development efforts, potential product characteristics and indications, marketing approvals and launches of other products, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing, the acceptance and demand of new pharmaceutical products, the impact of patents and other proprietary rights held by competitors and other third parties and the ability to obtain financing on favorable terms. The forward-looking statements in this press release reflect the Company’s judgment as of the date of this press release. The Company disclaims any intent or obligation to update these forward-looking statements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of our securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.Contact:
Ashley Ray
aray@olmsteadwilliams.com
310.824.9000 (office), 919.630.5508 (cell)

Original story can be found at: http://www.globenewswire.com/news-release/2019/08/21/1904761/0/en/CURE-Pharmaceutical-OTCQB-CURR-Takes-First-Step-To-Secure-Hemp-CBD-Supply-Chain-by-Partnering-with-Fytiko-Farms.html?f=22&fvtc=5&fvtv=41223728

Continue Reading

Trending